Patients HCP
This site is for US Health Care Professionals only
Banner background
Mechanism of Action

Mechanism of Action

Watch to learn about the mechanism of action for TABRECTA® (capmatinib) tablets. Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
A Strong Start to mNSCLC Diagnosis TABRECTA Video

Testing: A Strong Start to mNSCLC Diagnosis

Hear a nurse navigator's perspective on how comprehensive biomarker testing can give patients a strong start to diagnosis in mNSCLC.
TABRECTA: An Overview and Deep Dive into the GEOMETRY mono-1 Trial

TABRECTA: An Overview and Deep Dive Into the GEOMETRY mono-1 Trial

Watch a renowned clinical expert provide a detailed review of TABRECTA® (capmatinib) tablets, including the role of METex14 in NSCLC pathogenesis, the GEOMETRY mono-1 trial, patient identification, and AE management.

Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis. ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA. ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in the GEOMETRY mono-1 study, with 1.9% of...

Indication

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION